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Ewing’s sarcoma (ES) is a rare tumor that is most common in children and young adults. Late eﬀects of ES therapy include second
cancers, a tragic outcome for survivors of such a young age. This paper will explore the frequencies and types of malignancies
that occur after ES. Additionally, it will review how second malignancies have changed with the shift in treatment from high-
dose radiation to chemotherapy regimens including alkylators and epipodophyllotoxins. The risk of additional cancers in ES
survivors will also be compared to survivors of other childhood cancers. Finally, the possible genetic contribution to ES and
second malignancies will be discussed.
1.Introduction
T h e5 - y e a rs u r v i v a lr a t ef o rE w i n g ’ ss a r c o m a / E w i n g ’ ss a r -
coma family of tumors (ES) has increased from <20%
prior to the use of systemic therapy in the early 1970’s [1]
to around 70% with current therapy in localized disease
[2]. This improvement in survival is credited to improved
surgical techniques, reﬁnements in radiation therapy, and
intensiﬁed multiagent chemotherapy. In ES as well as in
all childhood cancers, late eﬀects are being discovered as
survival rates improve and the survivor pool enlarges. Sub-
sequent malignant neoplasms (SMN) have been recognized
as a particularly tragic late eﬀect of childhood cancer
therapy. Radiation therapy (RT), anthracyclines, alkylators,
and epipodophyllotoxins are all used in modern ES therapy
and have been associated with SMN. This paper will review
the rates of and common types of SMN after ES therapy, the
changes in SMN as ES therapy has changed over time, and
risk of SMN in ES survivors compared to survivors of other
childhood cancers.
2. Incidenceof Second Malignanciesafter
Ewing’s Sarcoma
2.1. Radiation Treatment Era. The original reports of SMN
after ES therapy were most notable for high rates of
secondary bone cancers. The Late Eﬀects Study Group ﬁrst
reported on SMN in ES and osteosarcoma (OS) survivors
together. They found a SMN annual incidence of 148.5 per
100,000 per year in the 1,066 bone tumor survivors [3].
Patients included in this report were treated from 1950
through 1970. No hematologic SMN were reported, but
62.5% of the SMN were bone or soft tissue sarcomas (STS).
Other SMN included one each of breast cancer, brain tumor,
and nondisclosed cancer type. This high rate of secondary
s a r c o m a sw o u l db ee x p e c t e di na nE St r e a t m e n te r aw h e n
many patients would have been treated with high-dose RT
only. The grouping of ES and OS together, however, makes
it diﬃcult to determine a true risk of SMN for ES survivors
given that the cohort may include OS patients with a high
genetic risk for SMN (e.g. germline p53 mutations/ Li-
Fraumeni Syndrome(LFS)). An updated report from the
same group in 1987 looked speciﬁcally at secondary bone
cancers by primary cancer type. Patients with a primary
ES had a relative risk (RR) of 649 and an absolute excess
risk (AER) of 59.6 per 100,000 per year for secondary bone
tumors. It was also noted that the risk of secondary bone
tumors(notspeciﬁctoESprimary) washighestinthosewho
received >60Gy [4].
Six of 24 long-term survivors treated at MD Anderson in
the 1970’s developed SMN in the RT ﬁeld; four of these were
OS [5]. A brief report of early Surveillance, Epidemiology,2 Sarcoma
and End Results Program (SEER) data found a cumulative
SMN incidence of 2.2% in those who had survived ES for
greater than 5 years, with an observed/expected (O/E) ratio
of8.5[6].Theregistryincludedpatientstreatedinthe1980’s,
and while the majority of SMN were various solid tumors, a
small number of secondary myeloid leukemias were noted.
A small study of 76 ES patients from Iowa looked at the
incidence of late eﬀects by local control modality. All 3
patients that developed SMN had RT only for local control.
SMN included one each of OS, cervical cancer, and breast
cancer [7]. Kuttesch Jr. et al. reviewed 266 ES survivors
treated prior to 1990 from 3 institutions with a median
followup of 9.5 years found 16 SMN, 14 of which were solid
tumors (10 sarcomas, 3 carcinomas, and one meningioma).
Risk of SMN was higher in those who received RT compared
to those who did not, and the risk of secondary sarcoma was
higher with higher RT dose. The reported cumulative rate
of SMN was 9.2% at 20 years [8]. In summary, the above
studies point out the high risk of secondary malignancies
(particularly sarcomas within the radiation ﬁeld) for ES
patients who receive radiation. Although they include small
numbers of patients, the reports note a trend of increasing
risk of SMN with increasing radiation dose.
2.2. Chemotherapy Treatment Era Prior to Standard High-
Dose Alkylators and Epipodophyllotoxins. More detailed
reports focused solely on SMN in survivors of ES have
come forth since the original limited studies above. The
largest of these studies are summarized in Table 1. In the
Kuttesch Jr et al. review that was described above, only
7.9% of patients did not receive radiation. Most patients
receivedcyclophosphamide(97%)anddoxorubicin(86%)at
median doses of 10,900mg/m2 and 394mg/m2,r e s p e c t i v e l y .
Most patients did not receive etoposide (18%) or ifosfamide
(15%). Only 2 of the 16 SMN were hematologic, one each of
lymphoid and myeloid leukemias [8].
Averylong-termfollowupofpatientstreatedattheMayo
Clinic between 1960 and 1980 revealed a 7.3% overall rate
of SMN in a group of patients whose overall survival rate
was just 22%. The majority of patients received vincristine,
dactinomycin,cyclophosphamide,anddoxorubicin(VACA).
SMNincludedonesarcomaandtwocarcinomas.Allpatients
with SMN had received RT, however the SMN occurred in
the RT ﬁeld in only one of these three patients [9].
McLean et al. reviewed the Dana Farber Cancer Institute
experience between 1971 and 1988 at a median 10.2 year
survival in 82 patients treated for ES. Seventy-ﬁve (91.5%)
patients received vincristine, actinomycin, and cyclophos-
phamide (VAC) or VACA. Seven patients developed SMN
at a median latency of 14.4 years from primary diagnosis.
Foursarcomas,onecarcinoma,and2hematologicSMNwere
noted. The cumulative risk of SMN was 6.7% and 42.8% at
10 and 20 years, respectively. Although primary therapy did
not include ifosfamide and etoposide (IE), the single patient
who developed secondary acute myeloid leukemia (AML)
had received these drugs for recurrent ES. No diﬀerence
in risk was found based on radiation dose or doxorubicin
administration [10].
As chemotherapy protocols for ES started to include
higher doses of alkylators, but still prior to the routine
use of etoposide, the ratio of solid to hematologic SMN
began to decrease. A review of the German experience from
1981–1991 included a majority of patients treated with
VACA with some high-risk patients treated with vincristine,
actinomycin, ifosfamide, and doxorubicin (VAIA). They
reported an overall rate of SMN of 1.2% after ES with a
relatively short median followup of 5.1 years. No treatment
factors were found to be statistically signiﬁcant in predicting
the development of SMN, although there was a trend toward
more solid tumor SMN in those who were treated with RT.
The three solid tumor SMN (all sarcomas) were diagnosed at
6.8, 9.8, and 11.4 years after ES treatment, while all but one
of the ﬁve hematologic SMN were diagnosed within 3 years
of ES treatment [11].
The Rizzoli Institute in Italy ﬁrst reported on their
SMN ﬁndings after ES therapy in 1989. At that time, they
found 4 out of 144 localized ES survivors developed 3
radiation induced sarcomas and one acute lymphoblastic
leukemia (ALL) [12]. Their more recent review of 597 ES
patients found 14 SMN, 11 of which were solid tumors.
Similar to other reports, they found the risk for SMN to be
higher with higher doses of radiation. The mean followup
of patients who developed a hematologic SMN was shorter
thanthosewhodevelopedasolidtumorSMN.Theestimated
rate of any SMN at 5, 10, and 20 years after original
diagnosis was 3%, 6.5%, and 12.7% respectively [13]. When
analyzed by chemotherapy regimen, the SMN rate was
5.9% after vincristine, doxorubicin, and cyclophosphamide
(VDC), 1.8% after VACA, and 1.7% after VACA plus IE with
median followup for each group of 7.6, 7.4, and 4.1 years;
respectively.
The Childhood Cancer Survivor Study (CCSS) is a
well-described multiinstitutional cohort of pediatric cancer
patients treated between 1970 and 1986 with a minimum
5-year survival. Information for the CCSS was gained via
self-reportquestionnaires,butSMNwereconﬁrmedthrough
medical record review when reported. Cervical dysplasia,
nonmelanoma skin cancer (NMSC), meningiomas, and
SMN that occurred prior to inclusion (i.e., less than 5 years
from the time of primary cancer diagnosis) were speciﬁcally
excluded. The CCSS recently reported long-term outcomes
of the ES patients in their cohort and found 36 SMN in 34
of the 403 patients, or a cumulative incidence of 9% [14].
The median time from ﬁrst diagnosis to SMN was 14.5 years.
Of the 34 patients who developed SMN, 26 (86.7%) received
radiation. The SIR in all survivors, those who received
radiation, and those who did not receive radiation, was 5.9,
6.6, and 3.3, respectively. Notably, 11 women developed 13
breast cancers, 7 of which were in the radiation ﬁeld. The
SIR for subsequent breast cancer after whole-lung radiation
(1200–1500cGy) was 36.0. Only 2 hematologic SMN were
reported.
These six studies demonstrate that as chemotherapy
became standard in ES therapy, but before the routine use of
IE, hematologic SMN became more common. Solid tumor
SMN continued to occur, still most commonly after RT
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2.3. Chemotherapy Treatment Era: High Dose Alkylators
and Epipodophyllotoxins. The distinction of patients who
received high-dose alkylators and epipodophyllotoxins is
important due to the distinct risk of secondary AML/
myelodysplastic syndrome (MDS) that follows exposure
to these agents. In particular, cyclophosphamide has been
linked to monosomy 5 and monosomy 7 associated MDS
with a latency of 5 years or more, and etoposide has been
linked to 11q23 associated AML with a latency of 2 years or
less [15–17].
The ﬁrst American cooperative group trial (com-
bined Children’s Cancer Group/Pediatric Oncology Group
(CCG/POG) INT-0091) to add IE to standard frontline
therapy accrued patients from 1988 to 1992. This study ran-
domizedpatientstoVACA(RegimenA)orVACAalternating
with IE (Regimen B) with stratiﬁcation for the presence of
metastases. Due to excellent accrual, a third arm was added.
This arm (Regimen C) assigned patients with metastatic
disease to VDC alternating with IE, but with cumulative
doses of ifosfamide 140g/m2, cyclophosphamide 17.6g/m2,
anddoxorubicin450mg/m2 (comparedto90g/m2,9.6g/m 2,
and 375mg/m2, resp., on Regimen B). Seven of 398 par-
ticipants without metastatic disease developed a nSMN.
Four SMN were hematologic and 3 SMN were solid tumors
(2 sarcomas and one ovarian tumor). No diﬀerences were
found in SMN rates for the standard (Regimen A) versus
experimental (Regimen B) arms, however, it is not reported
ifhematologicSMNweremorecommonintheexperimental
arm [2]. When patients with localized and metastatic disease
were evaluated, twelve patients developed a hematologic
SMN at a median of 8.03 years and only one additional
solid tumor SMN was found in addition to the prior report
[18]. Six of the additional 8 patients with hematologic
SMN received therapy per Regimen C. In a multivariate
analysis of the patients with secondary AML or MDS, only
treatment Regimen C was associated with increased risk.
The overall rate of secondary AML/MDS was 2% at 5 years,
but was 11% in those treated on Regimen C. Patients were
analyzed in regard to granulocyte colony stimulating factor
(G-CSF) exposure, and no dose relation risk was noted for
the development of AML/MDS [18]. A larger review of
recent CCG/POG legacy ES protocols, which included the
above study, found 9 solid tumor SMN in 1,156 patients.
Cumulative incidence for solid tumor SMN after ES was
1.8% at 10 years. This paper also evaluated SMN after OS,
and the solid tumor SMN risk in the combined ES/OS group
was increased both in patients who received RT as well as
those exposed to etoposide and cyclophosphamide, all of
which are more likely in ES therapy than OS therapy [19].
The European Intergroup Cooperative Ewing’s Sarcoma
Study 92 (EICESS-92) enrolled 690 evaluable patients with
ES from 1992 to 1999. Standard risk patients were ran-
domized to VAIA alone or VAIA for four courses then
completion of therapy with VACA and high-risk patients
was randomized to VAIA or etoposide plus VAIA. Six SMN
were reported for a total incidence of 0.93%, at the short
median followup of 56 months. There was one secondary
sarcoma, one secondary carcinoma, two cases of ALL, and
two cases of AML/MDS, both with monosomy 7. There was
a trend toward increased risk of SMN in patients exposed
to etoposide. Standardized incidence ratios (SIRs) for the
hematologic SMN were calculated and were 33.4 and 30.9
compared to SEER and the Saarland Registry populations,
respectively [20]. The strikingly low rate of SMN in this
study (predominantly composed of hematologic SMN) may
be due to median followup of less than ﬁve years, as solid
tumor SMN have been shown to have a longer latency than
hematologic SMN.
A Memorial Sloan Kettering Cancer Center protocol uti-
lizedforsarcomasinthe1990’swasreviewedforriskofSMN.
All patients received 16,800mg/m2 of cyclophosphamide,
300mg/m2 of doxorubicin, 27,000mg/m2 of ifosfamide, and
1,500mg/m2 of etoposide. Most patients had ES, but some
patients with desmoplastic small round-cell tumor and other
sarcomaswereincluded.Fiveof86patients(5.8%)developed
AML by the median followup of 24 months. The 40 month
cumulative incidence of AML was 8% [21]. Of note, the
cumulative doses of both ifosfamide and etoposide used
in this protocol were lower than the current Children’s
Oncology Group (COG) standard for ES.
Ar e p o r tf r o mS tJ u d e ’ sC h i l d r e n ’ sR e s e a r c hH o s p i t a l
records revealed 12 SMN, 8 hematologic, and 4 solid tumors,
in 237 patients treated for ES. This was a cumulative
incidence of 5.1%, with 5 and 10 year rates of 3% and
4.7%, respectively. When compared to SEER cancer rates,
this was a SIR of 17.8 with AER of 5.4%. All but one of
the eight diﬀerent protocols examined included IE, with the
ifosfamide dose for the 3 most recent protocols being 33%
higher than in earlier regimens. The risk for SMN was noted
to be higher in those treated on more recent protocols and
in those with a lower stage at diagnosis, presumably due to
increased survival and thus increased followup time [22].
These six reports, in which the vast majority of patients
were exposed to high-dose alkylators and/or epipodophyllo-
toxins,highlighttheincreaseofhematologicSMN(especially
myeloid) at a short latency after therapy.
2.4. Mixed Treatment Era. The following studies are notable
for their lack of description of treatment speciﬁcs and/or
the inclusion of patients treated in diﬀerent treatment eras
to allow for the inclusion of large numbers of patients. The
previously reviewed Mayo Clinic followup was updated to
include patients treated in more recent years (1975–1999)
and found 29 SMN in 397 ES patients [23]. This correlates
to a SMN rate of 6.5%, including hematologic SMN, at a
muchshorterfollowupthanthepriorreportfromthisgroup.
Chemotherapy regimens were not speciﬁcally described in
this report.
A single institution Dutch review of patients with
extraosseous ES treated from 1979–2008 found a single
patient out of 16 that had both a second and third
cancer (breast tumors with diﬀerent histologies) in the
local radiation ﬁeld. No speciﬁcs of chemotherapy regimens
were noted, other than the use of both soft tissue sarcoma
and ES protocols. Mean followup was 8.4 years [24]. A
Turkish report of a minimum 3 year followup of childhood
cancer survivors reported two of 30 (6.6%) ES patients4 Sarcoma
had developed SMN [25]. This study is most notable for a
very high lost to followup rate of 65%, which may vastly
underestimate SMN risk. SMN were reported at a rate of 7%
at a mean of 13.1 years in ES survivors treated at the National
Cancer Institute from 1965–1992 [26].
ES patients who received stem-cell transplant for
metastatic, refractory, or recurrent disease on the high risk
EICESS protocol from 1986–1994 were analyzed for SMN.
Of the 36 patients who underwent transplant, 26 were
autologous and 10 were allogeneic. While chemotherapy
regimens varied, all patients received total body irradiation
as part of their preparatory regimen. Median followup was
7.4years fromdiagnosis and 6.7years fromtransplant. There
were 2 cases of secondary MDS and 1 case of liposarcoma,
leading to a cumulative incidence of 8.3% in a population in
which 50% of patients died of disease [27].
T h em o s tr e c e n ta n dl a r g e s tr e p o r to fs e c o n dm a l i g -
nancies in a cohort of ES patients is from the SEER data.
The SEER registries collect cancer diagnosis and treatment
information from various geographic regions of the United
States, covering about 10% of the country’s population [28].
Sultanet al. reviewed patients in the SEER databasethat were
diagnosed with ES between 1973 and 2005. Of 1,166 patients
with ES, 35 developed a SMN. SMN was more common in
patients treated in an earlier time period (1973–1985) and
with RT compared to patients who did not develop SMN.
There was no diﬀerence in rates of radiation between those
who developed solid tumors versus hematologic malignan-
cies. Hematologic malignancies were more common in the
later time periods (1985–2005), consistent with the standard
use of etoposide during these periods. Hematologic SMN
occurred after a shorter latency from diagnosis (36 months
versus 98 months for solid tumors), as noted in many of
the above reports. The estimated risks of SMN at 5, 10,
and 20 years after original diagnosis were 2.1%, 4.4%, and
8%, respectively. The risk of SMN was higher in patients
diagnosed with ES before the age of 20 years. Two of these
patients developed third malignancies [29].
3. Typesof Second Malignanciesafter
Ewing’s Sarcoma
The most common solid tumor SMN after ES is OS,
followed by malignant ﬁbrous histiocytoma (MFH) [8, 13,
23, 30, 31]. OS has been noted to comprise about 50–
60% [8, 10, 31, 32] of solid tumor SMN, although OS
has made up a smaller percentage after therapy in more
recent eras [19]. Cases of neuroblastoma [14, 29], neu-
roepithelioma [29], teratocarcinoma [29], germinoma [29],
endometrial sarcoma [29], liposarcoma [20, 23, 27], spindle
cell sarcoma [9], dermatoﬁbrosarcoma [29], ﬁbroscarcoma
[8, 23], undiﬀerentiated sarcoma [19], malignant melanoma
[13, 29], anaplastic astrocytoma [19], breast cancer [23, 24,
31, 33], clear cell adenocarcinoma [29], papillary thyroid
cancer [19, 22, 23, 34], renal cell carcinoma [19], malignant
thymoma[6],palatal[10]andparotid[35]mucoepidermoid
carcinoma, colon cancer [6], gastric adenocarcinoma [10],
bronchioalveolar carcinoma [8, 13] ,s m a l lc e l ll u n gc a n c e r
[13], squamous cell carcinoma of the cervix [22], and
squamous cell carcinoma of shoulder [20]h a v ea l lb e e n
reported after treatment for ES. Several of these solid tumor
SMN occurred far from the radiation ﬁeld or in patients who
received no RT [7, 34, 35]. Second benign neoplasms have
also been reported after ES, including prolactinoma [23],
uterine leiomyoma [23], breast ﬁbroadenoma [23], thyroid
adenoma [23] ,b a s a lc e l lc a r c i n o m a[ 8], and meningioma
[8], but due to diﬀerent methods of reporting their overall
rates are unknown. Carcinoma in situ of the cervix [8, 23]
has been noted in ES patients, some of whom had pelvic
o rv e r t e b r a lR T ,b u ti ti su n c l e a ri ft h e s eo c c u ra tr a t e s
diﬀerent from in the general population. Fuchs et al. noted
no diﬀerence in latency periods in the onset of secondary
sarcomas compared to carcinomas [23].
The most common hematologic SMN in all reports is
AML/MDS, which comprises about 60% of cases [18, 27,
29]. Other hematologic SMN include both B-cell and T-cell
lineage ALL [8, 12, 18, 20] Hodgkin lymphoma [10, 29],
non-Hodgkin lymphoma [29, 36], and multiple myeloma
[29].
Many of those who reported on outcomes after SMN
notebettersurvivalforthosewithsolidtumorsthanforthose
with hematologic SMN [11, 22, 29]. Fuchs et al. report poor
outcomes for secondary hematologic cancers and sarcomas,
with better outcomes in secondary carcinomas [23].
4.Risk of Second MalignanciesafterEwing’s
Compared to Other Childhood Cancers
The CCSS has reported the largest study comparing SMN
after a variety of primary pediatric cancers. While not all
cancer types were included in the cohort, the most common
pediatric cancers,including bone tumors,arerepresented.At
a median followup of 15.4 years, 314 SMN were reported
in the 13,581 CCSS cohort members. The cumulative rate
of SMN was 3.2% at 20 years after original diagnosis. The
SIR of the entire cohort was 6.38 when compared to SEER.
ThisparticularCCSSreportdidnotevaluatepatientswithES
separately, but rather they are included in the “bone tumor”
or “soft-tissue sarcoma” primary malignancy groups. SIR
for bone tumor primary was 4.5 with overall incidence of
2.05% at 20 years. There were no secondary leukemias in
patients with primary bone tumors and the overall rate of
SMN was 8.4% [37]. The probable reasons for the lack of
hematologic SMN in the bone cancer survivors in this study
include the treatment era of the cohort (prior to the standard
use of epipodophyllotoxins and high-dose alkylators) and
the exclusion of SMN that developed prior to 5 years from
original diagnosis, as noted previously.
A report of British survivors suggests that the risk of
bone tumors as SMN is higher after ES than other childhood
cancers, with a relative risk (RR) in ES of 267, secondary
only to those with heritable retinoblastoma (RR of 381) and
with all childhood cancer types with an RR of 43 [32]. Inskip
and Curtis’ review of SEER data found that ES survivors’
risk for any SMN (EAR 40.5) was second only to those with
primary Hodgkin lymphoma (EAR 43.2) [38]. One reviewSarcoma 5
Table 1
Author
(population
studied)
Median
Followup
Treatment
years
Total
patient
(#)
SMN
(#) SMN types Signiﬁcant Risks
for SMN
5/10/15/20
year SMN
rates
Risk calculation
Kuttesch, et al.
(NCI, SJCRH,
Florida)
9.5 years Prior to 1990 266 16 14 solid tumor
2 hematologic
Treating
institution, Any
RT, Higher
sarcoma risk with
higher RT (≥60
Gray) dose
NR
5%
NR
9.2%
AR = 33.8/10KPY
for sarcoma AR =
54.7/10KPY for
all SMN
Fuchs, et al.
(Mayo) 7.4 years 1975–1999 397 29 21 solid tumor
8 hematologic NR 6.5% at 7.4
years NR
Dunst, et al.
(CESS) 5.1 years 1981–1991 674 8 3 solid tumor
5 hematologic
None signiﬁcant,
Trend toward
increased solid
SMN with any RT
0.7%
2.9%
4.7%
NR
NR
Bacci, et al.
(Rizzoli)
Range of
5–33 years 1972–1999 597 14 11 solid tumor
3 hematologic
Higher for “full
dose” RT versus
post-op “reduced
dose”
3%
6.5%
NR
12.7%
NR
Ginsberg, et al.
(CCSS)
23 years
(mean) 1970–1986 403 36 34 solid tumor
2 hematologic NR 9% at 20
years
SIR = 5.9 AR =
48.1/10 K PY
Bhatia, et al.
(CCG/POG) 8.03 years 1988-1992 587 16 4 solid tumor
12 hematologic Treatment arm C NR SIR = 127.7 for
myeloid SMN
Paulussen, et al.
(EICESS) 4.6 years 1992-1999 690 6 2 solid tumor
4 hematologic
None signiﬁcant,
Trend toward
increased risk after
etoposide
0.93%
NR
NR
NR
SIR = 30.9–33.4
for hematologic
SMN (compared
to Saarland &
SEER registries)
Navid, et al.
(SJCRH) 12.2 years 1979–2004 237 12 4 solid tumor
8 hematologic
More recent
treatment
protocols, Lower
stage disease
3.0%
4.7%
NR
NR
SIR = 17.8 overall
SIR = 65.1 on
more recent
protocols
Sultan, et al.
(SEER) 6.7 years 1973–2005 1166 35 23 solid tumor
12 hematologic
Treatment era
(1973–85), Any
radiation (OR =
2.55)
2.1%
4.4%
NR
8.0%
O/E =4.01
O/E = 51.09 for
myeloid SMN
O/E = 51.08 for
OS
Abbreviations: SMN: second malignant neoplasm, NCI: National Cancer Institute, SJCRH: St Jude Children’s Research Hospital, CESS: Cooperative Ewing’s
Sarcoma Study, CCG: Children’s Cancer Group, POG: Pediatric Oncology Group, EICESS: European Intergroup Cooperative Ewing’s Sarcoma Study, SEER:
Surveillance, Epidemiology and End Results, RT: radiation therapy, NR: not reported, AR: absolute risk, PY: person years, OR: odds ratio, SIR: standardized
incidence ratio, O/E ratio of observed to expected cases OS: osteosarcoma
of secondary STS noted the highest risk was in those whose
primary tumor was ES, who had a 7.2 times risk compared
to other diagnoses. The SIR for STS after ES was 327, with
the next closest being Hodgkin lymphoma and primary STS
with SIRs of 73 and 75, respectively [39].
The CCSS noted that secondary breast cancers in women
not exposed to chest RT are most common in bone and
STS primaries. SIRs for secondary breast cancers after RT for
Hodgkin lymphoma were 26.3 and bone sarcomas were 19.4
[33]. No rate was speciﬁcally noted for ES survivors, again
makingitdiﬃculttoknow ifgeneticallypredisposed patients
such as those with LFS are included in this rate.
Long-term followup of Dutch childhood cancer sur-
vivors treated between 1966 and 1996 revealed a mortality
rate from SMN of 1.4% at 16.1 years [40], without disease-
speciﬁc rates reported. A review of the Nordic cancer registry
found a cumulative incidence of 1.07% of SMN in pediatric
patientsdiagnosed withachildhood cancerfrom1960–1987,
with the rate reaching 3.5% in 25-year survivors. There was
a higher RR of SMN in those exposed to RT, and patients
withlymphomasmadeup25%ofthosewhodevelopedSMN
[41].
5. GeneticContributiontoEwing’sSarcomaand
Secondary Malignancies
One of the distinguishing features of ES is the predominance
of the (11; 22) (q24;q12) chromosomal translocation that6 Sarcoma
encodes the EWS/FLI-1 oncoprotein. Many recent molecular
advances have been made in understanding the pathogenesis
of ES [42] and these other involved pathways may oﬀer
an informative perspective to explain the high incidence
of secondary malignancies seen in ES (and the risk of ES
as SMN). Alterations in the retinoblastoma (RB) pathway
are thought to be cooperating mutations in ES [43], and
ES occurring as SMN after treatment for heritable RB
continue to be described in the literature [44–49]. Perhaps
theunderlyinggermlineRBmutationsfoundinpatientswith
heritable RB combine with acquired EWS/FLI-1 transloca-
tions in mesenchymal or neuroectodermal tissues to create
the necessary alterations to develop ES as SMN in RB
patients.
Interestingly, no known hereditary cancer syndromes
have ever been associated with ES (other than the RB
connection described above). However, the possibility of ES
predisposition genes have been discussed based on epidemi-
ological evidence [50]. In particular, the repeated association
between ES and hernias [51], the association between ES
and increased paternal age [52], sibling reports [53, 54], and
the repeated observation that ES almost exclusively occurs in
Caucasians [55] suggest some type of genetic contribution to
risk of ES. One could speculate that this same genetic risk,
even if only modest, contributes to the observed increased
risk of SMN after treatment for ES compared to other
childhood cancers. As more research is done on the genetic
epidemiology of ES, a better understanding of increased
SMN risk in ES may become clear.
6. Discussion
The incidence of SMN after ES treatment has varied in
many reports. Much of this variation is due to the changing
therapiesthroughoutdiﬀerenttreatmenteras.Thefrequency
of RT in all childhood cancer therapy has decreased from
56% in 1973–79 to 28% in 1995–2002 [38], and this trend
has been followed in ES treatment protocols. Although solid
tumor SMN have decreased in frequency, many reports note
signiﬁcantly increased risk in patients who received RT or
with increased RT dose. Hematologic SMN have increased
with intensiﬁed chemotherapy regimens containing high-
dose alkylators and epipodophyllotoxins, which are known
to cause secondary leukemias. Since hematologic SMN
generally have a shorter latency period than solid tumor
SMN, solid tumor SMN are likely to be underrepresented
in studies with short followup. Based on the reviews of ES
patients treated with current therapies, a likely estimate of all
SMN would be 5-6% at 10 years after diagnosis.
Intensiﬁcation of chemotherapy for ES has in part been
possible due to the use of G-CSF, but little information is
available regarding G-CSF’s potential role in hematologic
SMN. One study in ALL patients found secondary AML
rates were slightly increased in those who received G-CSF
compared to those who did not [56]. An analysis of AML
patients found a higher risk of relapse in those treated with
G-CSF who had increased quantities of G-CSF receptor (G-
CSFR) isoform IV in blasts at diagnosis [57]. This suggests
that there may be a subgroup of patients whose tumor
biology puts them at excess risk for malignancy when
etoposide and G-CSF are used in combination. While it is
not clear that such a relationship exists in ES patients, DNA
damage to hematopoeitic stem cells caused by intensiﬁed
chemotherapy may create leukemic blasts which are then
perpetuated by G-CSF leading to the high rate of leukemia
observed as ES-related SMN.
M a n yc o m p a r a t i v es t u d i e sh a v ef o u n dt h a tE Ss u r v i v o r s
have a higher risk of SMN compared to survivors of other
childhood cancers. While much of this risk can be attributed
to therapeuticmodalities, thereare alsohigher thanexpected
rates of SMN not clearly related to treatment. As discussed
above, ES is not clearly a part of any cancer predisposition
syndrome. However, ES tumors have been shown to contain
alterations in RB and p53 [58], which are known to be
mutated in hereditary RB and LFS, respectively. Considered
with the epidemiology data that suggests a mild to modest
genetic contribution to ES risk, the high rate of SMN after ES
raises the question if the underlying biology of ES patients
contributes to this excess SMN risk.
This paper is limited by the available data. The cited
reports used various statistical methods making it diﬃcult
to compare actual outcomes. Single cases may be reported
more than once, especially with the use of large population
databases such as SEER. Followup of SEER patients is limited
in that an SMN will not be reported if the patient has
movedoutofthecatchmentareasincetheprimarydiagnosis.
In some studies, most notably the CCSS cases would be
excluded if they developed SMN before surviving 5 years
from original diagnosis, leading to an underestimation of
SMN risk. None of the reports evaluated outcomes by
primary tumor site, which may or may not be similar to
outcomes by local control modality. Nevertheless, from this
paper one can conclude that ES survivors are at signiﬁcant
risk for SMN, particularly sarcomas and other solid tumors
in RT ﬁelds and for myeloid SMN after epipodophyllotoxin
and alkylator therapy. Additionally, but likely related in part
to ES therapy, the risk in these patients may be higher than
in those treated for other childhood cancers. ES survivors
should be educated on the risk of SMN and followed closely
throughout their lifetime.
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